RELISTOR has a well-established safety profile1

Most common adverse reactions

IN THE 4-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED PERIOD OF THE CLINICAL STUDY (N=401) (STUDY 1)1

||Adverse reactions occurring in at least 2% of patients receiving 3 RELISTOR 150-mg tablets (450 mg total) once daily and at an incidence greater than placebo.1

Includes: abdominal pain, upper abdominal pain, lower abdominal pain, abdominal discomfort, and abdominal tenderness.1

  • Adverse reactions of abdominal pain, diarrhea, hyperhidrosis, anxiety, rhinorrhea, and chills may reflect symptoms of opioid withdrawal1

RELISTOR’s molecular properties

  • RELISTOR is a uniquely methylated peripherally acting mu-opioid receptor antagonist (PAMORA)1
    • – Restricted from crossing the blood-brain barrier#
    • – No compromise of opioid-mediated analgesia in the central nervous system in clinical trials
  • RELISTOR is minimally metabolized and is excreted from the body primarily unchanged1:
    • – No significant pharmacokinetic drug-drug interactions1,11,**
    • – Only PAMORA for OIC not metabolized through the CYP3A4 pathway1,11

#Patients having disruptions to the blood-brain barrier may be at increased risk for opioid withdrawal and/or reduced analgesia and should be monitored for adequacy of analgesia and symptoms of opioid withdrawal.1

**Avoid concomitant use of RELISTOR with other opioid antagonists because of the potential for additive effects of opioid receptor antagonism and increased risk of opioid withdrawal.1

Download helpful resources for your patients Go now
See More
IMPORTANT SAFETY INFORMATION
  • RELISTOR tablets and injection are contraindicated in patients with known or suspected mechanical gastrointestinal obstruction and patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.
INDICATIONS
  • RELISTOR® is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.
IMPORTANT SAFETY INFORMATION
  • RELISTOR tablets and injection are contraindicated in patients with known or suspected mechanical gastrointestinal obstruction and patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.